Association between symptoms of acute cystitis and findings of bladder cancer in the Swedish standardized pathway for macroscopic haematuria
DOI:
https://doi.org/10.2340/sju.v60.45026Keywords:
Bladder cancer, cystitis, macroscopic hematuria, standardized care, pathwayAbstract
Standardized Care Pathway (SCP) for patients presenting with macroscopic haematuria was introduced in Sweden in 2015. In contrast to neighbouring countries, the Swedish model includes all patients with macroscopic haematuria above the age of 50, notwithstanding obvious causes. The aim of this study was to characterize the patients referred within the SCP and the presence of acute cystitis.
All patients admitted to two regional hospitals in 2023, under the terms of SCP macroscopic haematuria, were included. Patient data were collected retrospectively regarding age, sex, symptoms of cystitis and cause of haematuria.
The study included 782 patients. The median age was 70 years and half were women. In 89 cases, a urinary tract cancer was found (11%) and 74 (9%) had bladder cancer. The cancer-positive group was significantly older (median 75 years) and 76% were men. Half of patients (51%) had symptoms of acute cystitis on referral. This was significantly associated with the absence of bladder cancer, but only in the age groups 50–69, where no case was found among patients with symptoms of cystitis. In the age groups above, 22 cancer-positive patients (30% of all bladder cancer cases) had symptoms of cystitis.
The Swedish SCP macroscopic haematuria targets younger female patients unproportionally, in comparison to where cancer is likely found. Neither symptoms of cystitis, nor positive urine cultures exclude bladder cancer in elderly, but clearly in the age groups 50–69. If excluding the latter from the SCP, a 28% reduction of examined patients can be achieved with a negligible risk of missing cancer.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492
Malmström PU, Gårdmark T, Sherif A, Strock V, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016. Scand J Urol. 2019;53(4):193–9. https://doi.org/10.1080/21681805.2019.1632380 DOI: https://doi.org/10.1080/21681805.2019.1632380
Shapley M, Mansell G, Jordan JL, et al. Positive predictive values of >/=5% in primary care for cancer: systematic review. Br J Gen Pract. 2010;60(578):e366–77. https://doi.org/10.3399/bjgp10X515412 DOI: https://doi.org/10.3399/bjgp10X515412
Malmström PU, Skaaheim Haug E, Boström PJ, et al. Progress towards a Nordic standard for the investigation of hematuria: 2019. Scand J Urol. 2019;53(1):1–6. https://doi.org/10.1080/21681805.2018.1555187 DOI: https://doi.org/10.1080/21681805.2018.1555187
Holmäng S, Hedelin H. Standardized care pathway for bladder cancer in Sweden. So far lots of pain but little gain. Scand J Urol. 2022;56(3):233–4. https://doi.org/10.1080/21681805.2022.2078876 DOI: https://doi.org/10.1080/21681805.2022.2078876
Nilbert M, Bläckberg M, Ceberg J, et al. Diagnostic pathway efficacy for urinary tract cancer: population-based outcome of standardized evaluation for macroscopic haematuria. Scand J Urol. 2018;52(4):237–43. https://doi.org/10.1080/21681805.2018.1498124 DOI: https://doi.org/10.1080/21681805.2018.1498124
Vasdev N, Thorpe AC. Should the presence of a culture positive urinary tract infection exclude patients from rapid evaluation hematuria protocols? Urol Oncol. 2013;31(6):909–13. https://doi.org/10.1016/j.urolonc.2011.07.016 DOI: https://doi.org/10.1016/j.urolonc.2011.07.016
Luu T, Albarillo FS. Asymptomatic bacteriuria: prevalence, diagnosis, management, and current antimicrobial stewardship implementations. Am J Med. 2022;135(8):e236–44. https://doi.org/10.1016/j.amjmed.2022.03.015 DOI: https://doi.org/10.1016/j.amjmed.2022.03.015
Bollestad M, Vik I, Grude N, et al. Bacteriology in uncomplicated urinary tract infections in Norwegian general practice from 2001–2015. BJGP Open. 2018;1(4):bjgpopen17X101145. https://doi.org/10.3399/bjgpopen17X101145 DOI: https://doi.org/10.3399/bjgpopen17X101145
Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509–15. https://doi.org/10.1001/jamainternmed.2018.4204 DOI: https://doi.org/10.1001/jamainternmed.2018.4204
Vik I, Bollestad M, Grude N, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med. 2018;15(5):e1002569. https://doi.org/10.1371/journal.pmed.1002569 DOI: https://doi.org/10.1371/journal.pmed.1002569
Abuhasanein S, Jahnson S, Kjölhede H. Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics. BJUI Compass. 2024;5(2):261–8. https://doi.org/10.1002/bco2.301 DOI: https://doi.org/10.1002/bco2.301
Abuhasanein S, Jahnson S, Aljabery F, et al. Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. Scand J Urol. 2022;56(3):227–32. https://doi.org/10.1080/21681805.2022.2058605 DOI: https://doi.org/10.1080/21681805.2022.2058605
Elmussareh M, Young M, Ordell Sundelin M, et al. Outcomes of haematuria referrals: two-year data from a single large university hospital in Denmark. Scand J Urol. 2017;51(4):282–9. https://doi.org/10.1080/21681805.2017.1310759 DOI: https://doi.org/10.1080/21681805.2017.1310759
Boman H, Hedelin H, Holmäng S. The results of routine evaluation of adult patients with haematuria analysed according to referral form information with 2-year follow-up. Scand J Urol Nephrol. 2001;35(6):497–501. https://doi.org/10.1080/003655901753367613 DOI: https://doi.org/10.1080/003655901753367613
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14; discussion 14–5. https://doi.org/10.1016/j.eururo.2006.09.019 DOI: https://doi.org/10.1016/j.eururo.2006.09.019
Secher MS, Hyldgaard J, Jensen JB. The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy. Scand J Urol. 2023;57(1–6):10–4. https://doi.org/10.1080/21681805.2023.2166103 DOI: https://doi.org/10.1080/21681805.2023.2166103
Malmström PU. Time to abandon testing for microscopic haematuria in adults? BMJ. 2003;326(7393):813–5. https://doi.org/10.1136/bmj.326.7393.813 DOI: https://doi.org/10.1136/bmj.326.7393.813
Malmström PU, Truls G. Abandoning testing for asymptomatic microscopic haematuria in Sweden – a long-term follow-up. Scand J Urol. 2023;58:109–14. https://doi.org/10.2340/sju.v58.11142 DOI: https://doi.org/10.2340/sju.v58.11142
Lara J, Brunson A, Keegan TH, et al. Determinants of survival for adolescents and young adults with urothelial bladder cancer: results from the California Cancer Registry. J Urol. 2016;196(5):1378–82. https://doi.org/10.1016/j.juro.2016.05.082 DOI: https://doi.org/10.1016/j.juro.2016.05.082
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gustaf Starlander, Rami Shkair, Magnus Wagenius, Mats Bläckberg
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
